AstraZeneca PLC / Amplimmune Inc.

Solid Tumors (Immuno-oncology)

Disease Overview

Immuno-oncology agents block immune checkpoints (PD-1, PD-L1, CTLA-4) and unleash T-cell anti-tumor activity. By 2013, the field was transitioning from CTLA-4 (ipilimumab) to anti-PD-1 antibodies, with multiple companies racing to build complete checkpoint pipelines.

Competitive Landscape

When AstraZeneca/MedImmune acquired Amplimmune in August 2013, the anti-PD-1/PD-L1 race was crowded but still pre-approval: BMS's nivolumab (Opdivo) and Merck's pembrolizumab (Keytruda) led, with Roche's atezolizumab and AstraZeneca's own MEDI4736 (later durvalumab) close behind. AstraZeneca already had MEDI4736 (anti-PD-L1) and tremelimumab (anti-CTLA-4); the Amplimmune buy added AMP-514 (anti-PD-1 mAb, later MEDI0680), AMP-224 (B7-DC Fc fusion), AMP-110 and other B7-pathway preclinical assets, completing the checkpoint matrix per Drug Discovery News. Analyst reception was mixed-to-positive: Zacks viewed it as strategically sound given AstraZeneca's existing IO assets, while Seeking Alpha cautioned it offered 'no quick fixes' to revenue headwinds. AMP-514/MEDI0680 advanced to Phase 2 (kidney cancer, melanoma) but AstraZeneca discontinued the monotherapy program in February 2018, redirecting checkpoint efforts to durvalumab (Imfinzi). The deal is generally viewed as a defensive but ultimately commercially modest entry into PD-1.